<p>史赛克（NYSE:SYK - 获取免费报告）在周五发布给投资者的报告中，被华尔街 Zen 的研究分析师将评级从 “买入” 下调至 “持有”。</p>
<ul>
<li>如果你只能持有三项投资一辈子，请考虑这些</li>
</ul>
<p>其他一些研究公司也对 SYK 发表了看法。BTIG 研究在 4 月 14 日的研究报告中对史赛克的股票设定了 403.00 美元的目标价，并给予该公司 “买入” 评级。桑福德·C·伯恩斯坦在 5 月 5 日的研究报告中对史赛克的股票设定了 450.00 美元的目标价。Evercore ISI 在 5 月 2 日的报告中将史赛克的股票目标价从 400.00 美元下调至 390.00 美元，并对该股票设定了 “跑赢大盘” 的评级。花旗集团在 5 月 22 日的研究报告中重申了 “买入” 评级，并将史赛克的目标价设定为 455.00 美元（之前为 443.00 美元）。最后，JMP 证券在 5 月 5 日的报告中重新发布了对史赛克的 “市场表现” 评级。五位分析师对该股票给予了持有评级，十五位分析师则给予了买入评级。根据 MarketBeat 的数据，史赛克目前的平均评级为 “适度买入”，平均目标价为 427.30 美元。</p>
<p><strong>查看我们关于 SYK 的最新研究报告</strong></p>
<h2>史赛克股票表现</h2>
<ul>
<li>三只帮助将人工智能引入医疗保健的股票</li>
</ul>
<p>周五午盘交易中，NYSE SYK 的股票上涨了 1.05 美元，达到了 384.15 美元。该公司的股票交易量为 709,048 股，而其平均交易量为 1,331,290 股。该股票的 50 日移动平均价格为 370.10 美元，200 日移动平均价格为 376.03 美元。该公司的市值为 1466.3 亿美元，市盈率为 49.50，市盈增长比率为 2.93，贝塔系数为 0.93。史赛克的股价在一年内最低为 314.93 美元，最高为 406.19 美元。该公司的流动比率为 1.95，速动比率为 1.32，债务股本比率为 0.59。</p>
<p>史赛克（NYSE:SYK - 获取免费报告）最近在 5 月 1 日发布了季度财报。这家医疗技术公司报告每股收益（EPS）为 2.84 美元，超出分析师一致预期的 2.73 美元，超出幅度为 0.11 美元。该公司在本季度的收入为 58.7 亿美元，而一致预期为 56.8 亿美元。史赛克的股本回报率为 23.58%，净利润率为 13.25%。该公司本季度的收入同比增长了 11.9%。去年同期，该公司每股收益为 2.50 美元。研究分析师平均预测，史赛克在当前财政年度的每股收益将达到 13.47 美元。</p>
<h2>史赛克的内部交易</h2>
<ul>
<li>史赛克的收购狂潮：双位数增长在望</li>
</ul>
<p>在其他史赛克的新闻中，董事 Ronda E. Stryker 在 5 月 6 日的交易中出售了 200,000 股公司的股票。该股票以 376.96 美元的平均价格出售，总交易额为 75,392,000.00 美元。出售后，该董事现在持有 3,417,326 股公司股票，价值约为 1,288,195,208.96 美元。此次交易使其持股减少了 5.53%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。内部人士持有公司 5.90% 的股票。</p>
<h2>史赛克的机构交易</h2>
<p>最近，一些大型投资者对 SYK 的持仓进行了调整。Kohmann Bosshard Financial Services LLC 在第四季度收购了史赛克的新股份，价值 25,000 美元。Capital A Wealth Management LLC 在第四季度收购了约 26,000 美元的史赛克股票。Rakuten Securities Inc.在第四季度将其在史赛克的持股增加了 618.2%。Rakuten Securities Inc.现在拥有 79 股这家医疗技术公司的股票，价值 28,000 美元，此前在上个季度又购买了 68 股。Centricity Wealth Management LLC 在第四季度收购了约 30,000 美元的史赛克股票。最后，Goodman Advisory Group LLC 在第一季度收购了约 32,000 美元的史赛克股票。77.09% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于史赛克</h2>
<p>（获取免费报告）</p>
<p>史赛克公司是一家医疗技术公司。该公司通过两个部门运营，分别是医疗外科和神经技术，以及骨科和脊柱。骨科和脊柱部门提供用于全关节置换（如髋关节、膝关节和肩关节）以及创伤和四肢手术的植入物。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票</li>
<li>什么是财报？</li>
<li>大规模石油供应减少可能意味着这三只能源股的上涨</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>三只获得分析师罕见双重升级的股票</li>
<li>技术股票解析：关于科技你需要知道的</li>
<li>这家银行巨头刚刚获得 90 美元的目标价上调</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在史赛克吗？</h2>
<p>在你考虑史赛克之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而史赛克并不在名单上。</p>
<p>虽然史赛克目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

史赛克

<p>Wall Street Zen 最近将史赛克（NYSE:SYK）的评级从 “买入” 下调至 “持有”。其他公司对此有不同看法，BTIG Research 维持 “买入” 评级，目标价为 403 美元，而 Evercore ISI 将目标价从 400 美元下调至 390 美元。史赛克的股票目前交易价格为 384.15 美元，平均目标价为 427.30 美元。该公司报告了上个季度每股收益为 2.84 美元，超出预期，并且显示出同比收入增长 11.9%</p>

<p>Stryker (NYSE:SYK - Get Free Report) was downgraded by research analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Friday.</p>
<div class="lb-trans"><p>史赛克（NYSE:SYK - 获取免费报告）在周五发布给投资者的报告中，被华尔街 Zen 的研究分析师将评级从 “买入” 下调至 “持有”。</p>
</div><ul>
<li>If You Could Only Hold 3 Investments for Life, Consider These</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你只能持有三项投资一辈子，请考虑这些</li>
</ul>
</div><p>A number of other research firms have also weighed in on SYK. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a &#34;buy&#34; rating in a research note on Monday, April 14th. Sanford C. Bernstein set a $450.00 price target on shares of Stryker in a research report on Monday, May 5th. Evercore ISI lowered their price target on shares of Stryker from $400.00 to $390.00 and set an &#34;outperform&#34; rating on the stock in a report on Friday, May 2nd. Citigroup reiterated a &#34;buy&#34; rating and set a $455.00 target price (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, JMP Securities reissued a &#34;market perform&#34; rating on shares of Stryker in a report on Monday, May 5th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Stryker presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $427.30.</p>
<div class="lb-trans"><p>其他一些研究公司也对 SYK 发表了看法。BTIG 研究在 4 月 14 日的研究报告中对史赛克的股票设定了 403.00 美元的目标价，并给予该公司 “买入” 评级。桑福德·C·伯恩斯坦在 5 月 5 日的研究报告中对史赛克的股票设定了 450.00 美元的目标价。Evercore ISI 在 5 月 2 日的报告中将史赛克的股票目标价从 400.00 美元下调至 390.00 美元，并对该股票设定了 “跑赢大盘” 的评级。花旗集团在 5 月 22 日的研究报告中重申了 “买入” 评级，并将史赛克的目标价设定为 455.00 美元（之前为 443.00 美元）。最后，JMP 证券在 5 月 5 日的报告中重新发布了对史赛克的 “市场表现” 评级。五位分析师对该股票给予了持有评级，十五位分析师则给予了买入评级。根据 MarketBeat 的数据，史赛克目前的平均评级为 “适度买入”，平均目标价为 427.30 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on SYK</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 SYK 的最新研究报告</strong></p>
</div><h2>Stryker Stock Performance</h2>
<div class="lb-trans"><h2>史赛克股票表现</h2>
</div><ul>
<li>3 Stocks Helping to Bring AI to Healthcare</li>
</ul>
<div class="lb-trans"><ul>
<li>三只帮助将人工智能引入医疗保健的股票</li>
</ul>
</div><p>Shares of NYSE SYK traded up $1.05 during midday trading on Friday, hitting $384.15. The company's stock had a trading volume of 709,048 shares, compared to its average volume of 1,331,290. The stock has a fifty day moving average price of $370.10 and a 200 day moving average price of $376.03. The firm has a market capitalization of $146.63 billion, a price-to-earnings ratio of 49.50, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker has a one year low of $314.93 and a one year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.</p>
<div class="lb-trans"><p>周五午盘交易中，NYSE SYK 的股票上涨了 1.05 美元，达到了 384.15 美元。该公司的股票交易量为 709,048 股，而其平均交易量为 1,331,290 股。该股票的 50 日移动平均价格为 370.10 美元，200 日移动平均价格为 376.03 美元。该公司的市值为 1466.3 亿美元，市盈率为 49.50，市盈增长比率为 2.93，贝塔系数为 0.93。史赛克的股价在一年内最低为 314.93 美元，最高为 406.19 美元。该公司的流动比率为 1.95，速动比率为 1.32，债务股本比率为 0.59。</p>
</div><p>Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the company posted $2.50 EPS. On average, research analysts forecast that Stryker will post 13.47 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>史赛克（NYSE:SYK - 获取免费报告）最近在 5 月 1 日发布了季度财报。这家医疗技术公司报告每股收益（EPS）为 2.84 美元，超出分析师一致预期的 2.73 美元，超出幅度为 0.11 美元。该公司在本季度的收入为 58.7 亿美元，而一致预期为 56.8 亿美元。史赛克的股本回报率为 23.58%，净利润率为 13.25%。该公司本季度的收入同比增长了 11.9%。去年同期，该公司每股收益为 2.50 美元。研究分析师平均预测，史赛克在当前财政年度的每股收益将达到 13.47 美元。</p>
</div><h2>Insider Transactions at Stryker</h2>
<div class="lb-trans"><h2>史赛克的内部交易</h2>
</div><ul>
<li>Stryker’s Acquisition Spree: Double-Digit Growth on the Horizon</li>
</ul>
<div class="lb-trans"><ul>
<li>史赛克的收购狂潮：双位数增长在望</li>
</ul>
</div><p>In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Insiders own 5.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他史赛克的新闻中，董事 Ronda E. Stryker 在 5 月 6 日的交易中出售了 200,000 股公司的股票。该股票以 376.96 美元的平均价格出售，总交易额为 75,392,000.00 美元。出售后，该董事现在持有 3,417,326 股公司股票，价值约为 1,288,195,208.96 美元。此次交易使其持股减少了 5.53%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。内部人士持有公司 5.90% 的股票。</p>
</div><h2>Institutional Trading of Stryker</h2>
<div class="lb-trans"><h2>史赛克的机构交易</h2>
</div><p>Several large investors have recently made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker during the fourth quarter valued at $25,000. Capital A Wealth Management LLC acquired a new stake in shares of Stryker in the fourth quarter valued at about $26,000. Rakuten Securities Inc. boosted its holdings in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Stryker during the 4th quarter valued at about $30,000. Finally, Goodman Advisory Group LLC purchased a new stake in shares of Stryker during the 1st quarter valued at approximately $32,000. 77.09% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>最近，一些大型投资者对 SYK 的持仓进行了调整。Kohmann Bosshard Financial Services LLC 在第四季度收购了史赛克的新股份，价值 25,000 美元。Capital A Wealth Management LLC 在第四季度收购了约 26,000 美元的史赛克股票。Rakuten Securities Inc.在第四季度将其在史赛克的持股增加了 618.2%。Rakuten Securities Inc.现在拥有 79 股这家医疗技术公司的股票，价值 28,000 美元，此前在上个季度又购买了 68 股。Centricity Wealth Management LLC 在第四季度收购了约 30,000 美元的史赛克股票。最后，Goodman Advisory Group LLC 在第一季度收购了约 32,000 美元的史赛克股票。77.09% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Stryker</h2>
<div class="lb-trans"><h2>关于史赛克</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.</p>
<div class="lb-trans"><p>史赛克公司是一家医疗技术公司。该公司通过两个部门运营，分别是医疗外科和神经技术，以及骨科和脊柱。骨科和脊柱部门提供用于全关节置换（如髋关节、膝关节和肩关节）以及创伤和四肢手术的植入物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Stryker</li>
<li>What Are Earnings Reports?</li>
<li>A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>3 Stocks Getting Rare Double Upgrades From Analysts</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>This Banking Giant Just Got a $90 Price Target Upgrade</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票</li>
<li>什么是财报？</li>
<li>大规模石油供应减少可能意味着这三只能源股的上涨</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>三只获得分析师罕见双重升级的股票</li>
<li>技术股票解析：关于科技你需要知道的</li>
<li>这家银行巨头刚刚获得 90 美元的目标价上调</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=SYK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Stryker Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在史赛克吗？</h2>
</div><p>Before you consider Stryker, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑史赛克之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而史赛克并不在名单上。</p>
</div><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然史赛克目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

史赛克（NYSE:SYK）在 Wall Street Zen 被下调至 “持有” 评级